Dtsch Med Wochenschr 2017; 142(04): 261-266
DOI: 10.1055/s-0042-111608
Dossier
© Georg Thieme Verlag KG Stuttgart · New York

Mikrobiom und entzündliche Darmerkrankungen

Microbiome and Gut Inflammation
Daniel M. Autenrieth
,
Daniel C. Baumgart
Further Information

Publication History

Publication Date:
24 February 2017 (online)

Abstract

In the past decade the gut microbiome has received scientific attention like few other topics. It has become increasingly apparent that the commensal microbiota plays an important role in maintaining the health of the host. Changes of the microbiota composition or function coincide with different disorders such as infectious (i. e. Clostridium difficile infection) or inflammatory bowel diseases like Crohn’s disease or ulcerative colitis. Although the significance of this observation has not yet been fully elucidated and understood, several of attempts aimed at modulating the microbiota composition have been made. This article gives an update on current advances and clinical implications of the gut microbiome in infectious and inflammatory bowel diseases.

Durch die Verfügbarkeit großer metagenomischer Analyseverfahren hat sich unser Wissen über die menschliche Darmmikrobiota und deren Funktion um ein Vielfaches erweitert. Sie spielt eine große Rolle sowohl bei der Aufrechterhaltung der Wirtsgesundheit, aber auch bei der Pathogenese verschiedenster Erkrankungen. Lesen Sie hier, wie die Modulation der Darmmikrobiota als therapeutischer Ansatz genutzt werden kann und welche Rolle sie bei Infektionen mit Clostridium difficile und bei chronisch entzündlichen Darmerkrankungen spielt.

 
  • Literatur

  • 1 Hollister EB. Gao C. Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterology 2014; 146: 1449-1458
  • 2 Human Microbiome Project Consortium T. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486: 207-214
  • 3 Turnbaugh PJ. Quince C. Faith JJ. et al. Organismal, genetic, and transcriptional variation in the deeply sequenced gut microbiomes of identical twins. Proc Natl Acad Sci USA 2010; 107: 7503-7508
  • 4 Marchesi JR. Adams DH. Fava F. et al. The gut microbiota and host health: a new clinical frontier. Gut 2016; 65: 330-339
  • 5 Salzman NH. Underwood MA. Bevins CL. Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. Semin Immunol 2007; 19: 70-83
  • 6 Claesson MJ. Jeffery IB. Conde S. et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012; 488: 178-184
  • 7 Sobhani I. Tap J. Roudot-Thoraval F. et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 2011; 6: e16393
  • 8 Vaahtovuo J. Munukka E. Korkeamaki M. et al. Fecal microbiota in early rheumatoid arthritis. J Rheumatol 2008; 35: 1500-1505
  • 9 Wu GD. Chen J. Hoffmann C. et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 334: 105-108
  • 10 Moos WH. Faller DV. Harpp DN. et al. Microbiota and Neurological Disorders: A Gut Feeling. Biores Open Access 2016; 5: 137-145
  • 11 Kim M. Yu Z. Variations in 16S rRNA-based microbiome profiling between pyrosequencing runs and between pyrosequencing facilities. J Microbiol 2014; 52: 355-365
  • 12 Joint FAO/WHO Expert Consultation T. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Report of the Joint Food And Agriculture Organization (FAO) of the United Nations/ World Health Organization (WHO) Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Cordoba: FAO/WHO, 2001. Im Internet: http://www.fao.org/3/a-a0512e.pdf Stand: 04.12.2016
  • 13 Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord 2005; 5: 19-30
  • 14 Zhang F. Luo W. Shi Y. et al. Should we standardize the 1700-year-old fecal microbiota transplantation?. Am J Gastroenterol 2012; 107: 1755 author reply p.1755–1756
  • 15 Eiseman B. Silen W. Bascom GS. et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44: 854-859
  • 16 Borody T. Fischer M. Mitchell S. et al. Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead. Expert Rev Gastroenterol Hepatol 2015; 9: 1379-1391
  • 17 Wiegand PN. Nathwani D. Wilcox MH. et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012; 81: 1-14
  • 18 Voth DE. Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005; 18: 247-263
  • 19 McFarland LV. Elmer GW. Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769-1775
  • 20 Chang JY. Antonopoulos DA. Kalra A. et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197: 435-438
  • 21 Seekatz AM. Aas J. Gessert CE. et al. Recovery of the gut microbiome following fecal microbiota transplantation. MBio 2014; 5: e00893-e00814
  • 22 van Nood E. Vrieze A. Nieuwdorp M. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415
  • 23 Debast SB. Bauer MP. Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20 (Suppl. 02) 1-26
  • 24 Hagel S. Epple HJ. Feurle GE. et al. S2k-guideline gastrointestinal infectious diseases and Whipple's disease. Z Gastroenterol 2015; 53: 418-459
  • 25 Yang Z. Ramsey J. Hamza T. et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun 2015; 83: 822-831
  • 26 Reichert JM. Antibodies to watch in 2015. MAbs 2015; 7: 1-8
  • 27 Baumgart DC. Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369: 1627-1640
  • 28 Frank DN. Robertson CE. Hamm CM. et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 179-184
  • 29 Peterson DA. Frank DN. Pace NR. et al. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe 2008; 3: 417-427
  • 30 Barnich N. Denizot J. Darfeuille-Michaud A. E. coli-mediated gut inflammation in genetically predisposed Crohn's disease patients. Pathol Biol (Paris) 2013; 61: e65-e69
  • 31 Morgan XC. Tickle TL. Sokol H. et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012; 13: R79
  • 32 Rembacken BJ. Snelling AM. Hawkey PM. et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-639
  • 33 Kruis W. Fric P. Pokrotnieks J. et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623
  • 34 Lichtenstein L. Avni-Biron I. Ben-Bassat O. Probiotics and prebiotics in Crohn's disease therapies. Best Pract Res Clin Gastroenterol 2016; 30: 81-88
  • 35 Derikx LA. Dieleman LA. Hoentjen F. Probiotics and prebiotics in ulcerative colitis. Best Pract Res Clin Gastroenterol 2016; 30: 55-71
  • 36 Moayyedi P. Surette MG. Kim PT. et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology 2015; 149: 102-109.e6
  • 37 Rossen NG. MacDonald JK. de Vries EM. et al. Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. World J Gastroenterol 2015; 21: 5359-5371